COMMUNIQUÉS West-GlobeNewswire

WishBone Medical, Inc. announces new AlloMate Bone Pin System
05/09/2018
WARSAW, Ind., Sept. 05, 2018 (GLOBE NEWSWIRE) -- WishBone Medical, Inc. announces the official launch of the single-use, sterile packed AlloMate Bone Pin System for the maintenance of alignment and fixation of bone [...]
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
05/09/2018
EXTON, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today [...]
DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
05/09/2018
MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “ Company ” and “ DiaMedica ”) (TSX-V:DMA) (OTCQB:DMCAF) announces the recent appointment of Harry Alcorn Jr. Pharm.D. as Chief Medical [...]
Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors
05/09/2018
Dr. Heron Adds Deep Expertise in Orphan Drug Development and Commercialization Wayne, PA, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing [...]
PhaseBio Secures $34 Million in Series D Financing
05/09/2018
Proceeds will advance clinical development of PB2452, a potentially first-in-class reversal agent for patients on ticagrelor, and PB1046, a novel treatment for PAH MALVERN, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- [...]
Biotricity Developing ECG Patch for Anticipated Q1 2019 Release
05/09/2018
Biopatch to Extend Comprehensive Bioflux Solution with Advanced Diagnostics and High Usability REDWOOD CITY, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY ), a medical diagnostic and consumer [...]
Tyme Exceeds Enrollment Expectations for the Phase II Trial of SM-88 in Pancreatic Cancer
05/09/2018
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), today announced that the number of currently consented or randomized subjects has exceeded the enrollment target for the Stage 1 dose [...]
PetVivo Holdings, Inc. Welcomes Mr. Michael Haider as Senior Project Manager and Mr. Joel Hapke as Manager of Mfg., Analytical and Process Engineering
05/09/2018
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com ) MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- OTCPINK: PETV PetVivo Holdings, Inc. ( www.petvivo.com ) an emerging [...]
Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5
05/09/2018
Study finds no evidence of irritation or allergic reaction in any enrolled subject FRAMINGHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of [...]
FDA Confirms Target Decision Date for Novel Single-Vial Formulation of EGRIFTA® (Tesamorelin for Injection)
05/09/2018
MONTREAL, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies”) (TSX: TH) today announced that the Food and Drug Administration (“FDA”) has set the target date to November 3, 2018 to issue a [...]
La FDA confirme la date-cible pour une décision sur la nouvelle formulation en fiole unique d’EGRIFTA(MD) (tésamoréline pour injection)
05/09/2018
MONTRÉAL, 05 sept. 2018 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies ») (TSX: TH) a annoncé aujourd’hui que la Food and Drug Administration (« FDA ») a établi au 3 novembre 2018 la date-cible pour une [...]
KemPharm to Present at Two Healthcare Investor Conferences During September 2018
05/09/2018
CORALVILLE, Iowa, Sept. 05, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its President [...]
Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis
05/09/2018
Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRx Company announces DermiraConnect, a new patient access program that will provide patients broad access to QBREXZA Therapy is [...]
Opthea Receives Positive Interim Review from Independent Safety Committee in Phase 2b Wet AMD Clinical Trial
05/09/2018
MELBOURNE, Australia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, today announced that the [...]
Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage
05/09/2018
‒ Phase 3 Clinical Trial of NeoCart Did Not Meet Primary Endpoint of a Statistically Significant Improvement in Pain and Function in a Dual Threshold Responder Analysis One Year After Treatment as Compared to [...]
electroCore to Present Additional Research for Non-invasive Vagus Nerve Stimulation in Headache Disorders at the 17th Biennial Migraine Trust International Symposium
05/09/2018
BASKING RIDGE, N.J., Sept. 05, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that seven abstracts and an oral presentation featuring non- [...]
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
05/09/2018
QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course QR-110 was well-tolerated with no serious adverse events A Phase 2/3 pivotal [...]
Biohit GastroPanel® accurately predicted the progression of atrophic gastritis and its transition to gastric cancer in a European multicenter trial
05/09/2018
Biohit Oyj press release 05.09.2018 klo 10.10 local time (EEST) A Dutch research group working at Erasmus University (Rotterdam), headed by internationally recognized professor Kuipers, together with Norwegian [...]
Active Biotech regains global rights to development and commercialization of laquinimod
05/09/2018
PRESS RELEASE Lund Sweden, September 5, 2018 - Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that it regains the global development and commercialization rights to laquinimod from Teva Pharmaceutical [...]

Pages